Rentschler Biopharma appoints Uwe Buecheler as interim CEO
Esme Needham | January 26, 2026 | Appointment | | Rentschler Biopharma, interim CEO
Rentschler Biopharma, a contract development and manufacturing organisation (CDMO) specialising in biopharmaceutical products, has announced the appointment of Uwe Buecheler as interim CEO following the stepping down of current CEO Benedikt von Braunmuehl.
Buecheler, who is currently Vice Chairman of the Supervisory Board, will take on the role of interim CEO pending the appointment of a new CEO.
Buecheler brings more than 30 years of global biopharmaceutical experience to his role as interim CEO. He has served as Vice Chairman of the Supervisory Board at Rentschler since 2024, and also currently serves as Non-Executive Director at BioPhorum. Buecheler previously spent over 33 years at Boehringer Ingelheim, in roles including Senior Vice President Head of Business Unit Biopharmaceuticals and, most recently, Senior Advisor Biopharmaceuticals to the Board of Managing Directors.
Rentschler also announced the departure of Chief Operating Officer Christiane Bardroff following four years at the company. Her successor has been appointed and will later be announced by the Supervisory Board.
Nikolaus F Rentschler, chairman of the Supervisory Board, said of Buecheler: “He was closely involved in the development of our strategy and has many years of international leadership experience in navigating market dynamics and strategic decisions. He is well equipped to guide Rentschler during this phase, with the goal of creating value sustainably.”
Buecheler commented: “Building on the scale-up of our production capacity, our… development capabilities and successful efficiency improvements across our sites, we are leading Rentschler into the next phase of development.”
Rentschler provides process development and manufacturing, as well as consulting and regulatory support, to its biopharmaceutical clients.
